Immunosuppression of EAMG by IVIG is mediated by a disease-specific anti-immunoglobulin fraction

Annals of the New York Academy of Sciences

Volumn 1132, Issue , 2008, Pages 244-248

  Fuchs, Sara ^a   Feferman, Tali ^a   Meidler, Roberto ^b   Margalit, Raanan ^a   Sicsic, Camille ^c   Brenner, Talma ^c   Laub, Orgad ^b   Souroujon, Miriam C ^a,d  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b Omrix Biopharmaceuticals   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d OPEN UNIVERSITY OF ISRAEL   (Israel)

Author keywords

Experimental autoimmune myasthenia gravis (EAMG); Fractionation; Immunotherapy; Intravenous immunoglobulin (IVIG); Myasthenia gravis (MG)

Indexed keywords

IMMUNOGLOBULIN G;

ANIMAL MODEL; B LYMPHOCYTE; CELL PROLIFERATION; CHROMATOGRAPHY; CONFERENCE PAPER; ENZYME ACTIVITY; ENZYME RECONSTITUTION; FRACTIONATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYASTHENIA GRAVIS; NONHUMAN; RAT; TH1 CELL;

RATTUS;

EID: 45249088356     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1405.032     Document Type: Conference Paper

References (26)

1. Kazatchkine, M.D. & S.V. Kaveri. 2001. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345 : 747 755.
2. Dalakas, M.C. 2004. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol. Ther. 102 : 177 193.
3. Lemieux, R., R. Bazin & S. Neron. 2005. Therapeutic intravenous immunoglobulins. Mol. Immunol. 42 : 839 848.
4. Bayry, J., S. Lacroix-Desmazes, M.D. Kazatchkine, et al. 2007. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat. Clin. Pract. Rheumatol. 3 : 262 272.
5. Gold, R., M. Stangel & M.C. Dalakas. 2007. Drug Insight: the use of intravenous immunoglobulin in neurology - therapeutic considerations and practical issues. Nat. Clin. Pract. Neurol. 3 : 36 44.
6. Buchwald, B., R. Ahangari, A. Weishaupt, et al. 2002. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann. Neurol. 51 : 673 680.
7. Gajdos, P., H. Outin, D. Elkharrat, et al. 1984. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1 : 406 407.
8. Fateh-Moghadam, A., M. Wick, U. Besinger, et al. 1984. Hige dose intravenous gammaglobulin for myasthenia gravis. Lancet 1 : 848 849.
9. Edan, G. & F. Landgraf. 1994. Experience with intravenous immunoglobulin in myasthenia gravis: a review. J. Neurol. Neurosurg. Psychiatry 57 (Suppl 55 56.
10. Gajdos, P., S. Chevret, B. Clair, et al. 1997. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann. Neurol. 41 : 789 796.
11. Zhu, K.Y., T. Feferman, P.K. Maiti, et al. 2006. Intravenous immunoglobulin suppresses experimental myasthenia gravis: immunological mechanisms. J. Neuroimmunol. 176 : 187 197.
12. Fuchs S., T. Feferman, K.Y. Zhu, et al. 2007. Suppression of experimental autoimmune myasthenia gravis by intravenous immunoglobulin and isolation of a disease-specific IgG fraction. Ann. N.Y. Acad. Sci. 1110 : 550 558.
13. Fuchs, S., T. Feferman, R. Meidler, et al. 2008. A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis. J. Neoruimmunol. 194 : 89 96.
14. Samuelsson, A., T.L. Towers & J.V. Ravetch. 2001. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291 : 484 486.
15. Achiron, A., F. Mor, R. Margalit, et al. 2000. Suppression of experimental autoimmune encephalomyelitis by intravenously administered polyclonal immunoglobulins. J Autoimmun. 15 : 323 330.
16. Jorgensen, S.H. & P.S. Sorensen. 2005. Intravenous immunonoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. J. Neurol. Sci. 233 : 61 65.
17. Pashov, A., C. Dubey, S.V. Kaveri, et al. 1998. Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein. Eur. J. Immunol. 28 : 1823 1831.
18. Weishaupt, A., T. Kuhlmann, L.M. Schonrock, et al. 2002. Effects of intravenous immunoglobulins on T cell and oligodendrocyte apoptosis in high-dose antigen therapy in experimental autoimmune encephalomyelitis. Acta Neuropathol. (Berl.) 104 : 385 390.
19. Saoudi, A., V. Hurez, Y. de Kozak, et al. 1993. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int. Immunol. 5 : 1559 1567.
20. Wada, J., N. Shintani, K. Kikutani, et al. 2001. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition. Clin. Exp. Immunol. 124 : 282 289.
21. Jia, J. & M. Pollock. 2000. Treatment of rats with experimental allergic neuritis using high dose immunoglobulin. Chin. Med. J. (Engl.) 113 : 1096 1099.
22. George, J., L. Rauova, B. Gilburd, et al. 2001. The effect of intravenous immunoglobulins on the progression of experimental autoimmune myocarditis in the rat. Exp. Mol. Pathol. 71 : 55 62.
23. Shoenfeld, Y., L. Rauova, B. Gilburd, et al. 2002. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int. Immunol. 14 : 1303 1311.
24. Souroujon, M.C., D. Barchan & S. Fuchs. 1985. Analysis and modulation of the immune response of mice to acetylcholine receptor by anti-idiotypes. Immunol. Lett. 9 : 331 336.
25. Souroujon, M.C. & S. Fuchs. 1986. Idiotypes and anti-idiotypes in experimental autoimmune myasthenia gravis. Ann. N.Y. Acad. Sci. 475 : 81 93.
26. Kaneko, Y., F. Nimmerjahn & J.V. Ravetch. 2006. Anti- inflammatoryactivityof immunoglobulin G resulting from Fc sialylation. Science 313 : 670 673.